Phase 1b: APG-115+pembrolizumab
APG-115-US-002
Phase 2 small_molecule active
Quick answer
Phase 1b: APG-115+pembrolizumab for Unresectable or Metastatic Melanoma or Advanced Solid Tumors is a Phase 2 program (small_molecule) at Ascentage Pharma Group with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Ascentage Pharma Group
- Indication
- Unresectable or Metastatic Melanoma or Advanced Solid Tumors
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active